Combination therapies utilizing CTLA-4 and PD-L1 mAb blockade in early phase clinical studies have shown synergistic slowing of disease progression and extended PFS in adults with metastatic or unresectable sarcomas; however, they have not been tested in children (NCT02500797) (202, 203). Here, CTLA4 is linked to sarcoma.